Original paper
PDG20 Availability and Affordability of Oncologic Immunotherapies across Multiple-Countries
Abstract
While immunotherapies are reportedly effective without serious adverse effects, their high costs could limit their access. This study aimed to compare the access to the immunotherapy across multiple countries in terms of availability and affordability. This study targeted 7 Immune checkpoint inhibitors (Atezolizumab, Avelumab, Ipilimumab, Nivolumab, Pembrolizumab, Durvalumab, Cemiplimab) approved by US FDA as of April 2020 to compare their...
Paper Details
Title
PDG20 Availability and Affordability of Oncologic Immunotherapies across Multiple-Countries
Published Date
Sep 1, 2020
Volume
22
Pages
S41 - S41
Citation AnalysisPro
You’ll need to upgrade your plan to Pro
Looking to understand the true influence of a researcher’s work across journals & affiliations?
- Scinapse’s Top 10 Citation Journals & Affiliations graph reveals the quality and authenticity of citations received by a paper.
- Discover whether citations have been inflated due to self-citations, or if citations include institutional bias.
Notes
History